| Literature DB >> 26228695 |
Mahdi Mostafa1,2, Seyed Davar Siadat3, Fereshteh Shahcheraghi4, Farzam Vaziri5, Alireza Japoni-Nejad6, Jalil Vand Yousefi7, Bahareh Rajaei8, Elnaz Harifi Mood9, Nayyereh Ebrahim zadeh10, Arfa Moshiri11, Seyed Alireza Seyed Siamdoust12, Mohamad Rahbar13.
Abstract
BACKGROUND: To investigate antibiotic resistance, the occurrence and distribution of class 1 and 2 integrons in multidrug- resistant Staphylococcus aureus isolates from hospitals in Tehran, Iran. The isolates were examined for susceptibility to antimicrobial agents. The mecA gene, class 1 and 2 integrons were detected by PCR. Integrase positive strains were further analysed for the presence of resistance gene cassettes using specific primers and were sequenced.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26228695 PMCID: PMC4521504 DOI: 10.1186/s12866-015-0488-3
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Correlation of antibiotic resistance between class 1 integron-positive and integron-negative of S.aureus
| Antibiotics | All strains of S.aureus ( | Integron-positive isolates ( | Integron-negative isolates ( |
| |||
|---|---|---|---|---|---|---|---|
| R | S | R | S | R | S | ||
| AK* | 43 (31 %) | 96 (69 %) | 35 (34.7 %) | 66 (25.3 %) | 8 (21 %) | 30 (79 %) | 0.088 |
| SXT* | 38 (27.3 %) | 101 (72.7 %) | 34 (33.7 %) | 67 (66.3 %) | 4 (10.5 %) | 34 (89.5 %) | 0.004 |
| C* | 49 (32.3 %) | 90 (64.7 %) | 41 (40.6 %) | 60 (59.4 %) | 8 (21 %) | 30 (79 %) | 0.024 |
| TE* | 78 (56.1 %) | 61 (43.9 %) | 65 (64.4 %) | 36 (35.6 %) | 13 (34.2 %) | 25 (65.8 %) | 0.001 |
| CIP* | 56 (40.3 %) | 83 (59.7 %) | 49 (48.5 %) | 52 (51.5 %) | 7 (18.4 %) | 31 (81.6 %) | 0.001 |
| GM* | 76 (54.7 %) | 63 (45.3 %) | 68 (67.3 %) | 33 (32.7 %) | 8 (21 %) | 30 (79 %) | <0.001 |
| SPC* | 86 (61.9 %) | 53 (38.1 %) | 73 (72.3 %) | 28 (27.7 %) | 13 (34.2 %) | 25 (65.8 %) | <0.001 |
| ATH* | 69 (49.6 %) | 70 (50.4 %) | 62 (61.4 %) | 39 (38.6 %) | 7 (18.4 %) | 31 (81.6 %) | <0.001 |
| S* | 75 (54 %) | 64 (46 %) | 61 (60.4 %) | 40 (39.6 %) | 14 (37 %) | 24 (63 %) | 0.011 |
| GAT | 44 (31.7 %) | 95 (68.3 %) | 32 (31.7 %) | 69 (68.3 %) | 12 (31.6 %) | 26 (68.4 %) | 0.581 |
| OXA | 104 (74.8 %) | 35 (25.2 %) | 76 (75.2 %) | 25 (24.8 %) | 28 (73.7 %) | 10 (26.3 %) | 0.505 |
| PG | 137 (98.6 %) | 2 (1.4 %) | 101 (100 %) | 0 (0 %) | 36 (94.7 %) | 2 (5.3 %) | 0.073 |
| RP | 43 (31 %) | 96 (69 %) | 31 (30.7 %) | 70 (69.3 %) | 12 (31.6 %) | 26 (68.4) | 0.537 |
| LZD | 24 (17.3 %) | 115 (82.7 %) | 20(19.8 %) | 81 (80.2 %) | 4 (10.5 %) | 34 (89.5 %) | 0.149 |
| CD | 84 (60.4 %) | 55 (39.6 %) | 65 (64.4 %) | 36 (35.6 %) | 19 (50 %) | 19 (50 %) | 0.089 |
| E* | 95 (68.3 %) | 44 (31.7 %) | 78 (77.2 %) | 23(22.8 %) | 17 (44.7 %) | 21 (55.3 %) | <0.001 |
| TN | 66 (47.5 %) | 73 (52.5 %) | 46 (45.5 %) | 55 (54.5 %) | 20 (52.6 %) | 18 (47.4 %) | 0.289 |
| LEV* | 56 (40.3 %) | 83 (59.7 %) | 49 (48.5 %) | 52 (51.5 %) | 7 (18.7 %) | 31 (81.6 %) | 0.001 |
| CRO* | 71 (51.1 %) | 68 (48.9 %) | 66 (65.3 %) | 35 (34.7 %) | 5 (13.1 %) | 33 (86.9 %) | <0.001 |
*: significant values, AK Amikacin, SXT Trimethoprim- Sulfamethoxazole, C Chloramphenicol, TE Tetracycline, CIP Ciprofloxacin, GM Gentamicin, SPC Spectinomycin, ATH Azithromycine, S Streptomycin, GAT Gatifloxacin, OXA Oxacillin, PG Penicillin G, RP Rifampin, LZD Linezolid, CD Clindamycin, E Erythromycin, TN Tobramycin, LEV Levofloxacin, CRO Ceftriaxone; R Resistant, S sensitive
Correlation of antibiotic resistance between class 2 integron-positive and integron-negative of S. aureus
| Antibiotics | All strains of S.aureus ( | Integron-positive isolates ( | Integron-negative isolates ( |
| |||
|---|---|---|---|---|---|---|---|
| R | S | R | S | R | S | ||
| AK* | 43 (31 %) | 96 (69 %) | 21 (42.9 %) | 28 (57.1 %) | 22 (24.4 %) | 68 (75.6 %) | 0.021 |
| SXT* | 38 (27.3 %) | 101 (72.7 %) | 24 (49 %) | 25 (51 %) | 14 (15.5 %) | 76 (84.5 %) | <0.001 |
| C | 21 (42.9 %) | 28 (57.1 %) | 21 (42.9 %) | 28 (57.1 %) | 28 (31.1 %) | 62 (68.9 %) | 0.116 |
| TE* | 78 (56.1 %) | 61 (43.9 %) | 38 (77.5 %) | 11 (22.5 %) | 40 (44.4 %) | 50 (55.6 %) | <0.001 |
| CIP* | 56 (40.3 %) | 83 (59.7 %) | 28 (57.1 %) | 21 (42.9 %) | 28 (31.1 %) | 62 (68.9 %) | 0.003 |
| GM* | 76 (54.7 %) | 63 (45.3 %) | 37 (75.5 %) | 12 (24.5 %) | 39 (43.3 %) | 51 (56.7 %) | <0.001 |
| SPC* | 86 (61.9 %) | 53 (38.1 %) | 41 (83.7 %) | 8 (16.3 %) | 45 (50 %) | 45 (50 %) | <0.001 |
| ATH* | 69 (49.6 %) | 70 (50.4 %) | 36 (73.5 %) | 13 (26.5 %) | 33 (36.7 %) | 57 (63.3 %) | <0.001 |
| S* | 75 (54 %) | 64 (46 %) | 34 (69.4 %) | 15 (30.6 %) | 41 (45.6 %) | 49 (54.4 %) | 0.006 |
| GAT | 44 (31.7 %) | 95 (68.3 %) | 19 (38.8 %) | 30 (61.2 %) | 25 (27.8 %) | 65 (72.2 %) | 0.127 |
| OXA | 104 (74.8 %) | 35 (25.2 %) | 41 (83.7 %) | 8 (16.3 %) | 63 (70 %) | 27 (30 %) | 0.056 |
| PG | 137 (98.6 %) | 2 (1.4 %) | 49 (100 %) | 0 (0 %) | 88 (97.8 %) | 2 (2.2 %) | 0.418 |
| RP | 43 (31 %) | 96 (69 %) | 18 (36.7 %) | 31 (63.3 %) | 25 (27.8 %) | 65 (72.2) | 0.184 |
| LZD | 24 (17.3 %) | 115 (82.7 %) | 9 (18.4 %) | 40 (81.6 %) | 15 (16.7 %) | 75 (83.3 %) | 0.486 |
| CD | 84 (60.4 %) | 55 (39.6 %) | 34 (69.4 %) | 15 (30.6 %) | 50 (55.6 %) | 40 (44.4 %) | 0.078 |
| E* | 95 (68.3 %) | 44 (31.7 %) | 40 (81.6 %) | 9 (18.4 %) | 55 (61.1 %) | 35 (38.9 %) | 0.01 |
| TN | 66 (47.5 %) | 73 (52.5 %) | 26 (53 %) | 23 (47 %) | 40 (44.4 %) | 50 (55.6 %) | 0.214 |
| LEV* | 56 (40.3 %) | 83 (59.7 %) | 28 (57.1 %) | 21 (42.9 %) | 28 (31.1 %) | 62 (68.9 %) | 0.003 |
| CRO* | 71 (51.1 %) | 68 (48.9 %) | 38 (77.5 %) | 11 (22.5 %) | 33 (36.7 %) | 57 (63.3 %) | <0.001 |
*: significant values AK, Amikacin, SXT Trimethoprim- Sulfamethoxazole, C Chloramphenicol, TE Tetracycline, CIP Ciprofloxacin, GM Gentamicin, SPC Spectinomycin, ATH Azithromycine, S Streptomycin, GAT Gatifloxacin, OXA Oxacillin, PG Penicillin G, RP Rifampin, LZD Linezolid, CD Clindamycin, E Erythromycin, TN Tobramycin, LEV Levofloxacin, CRO Ceftriaxone, R Resistant, S sensitive
Fig. 1Distribution of mecA gene in MRSA isolates from nosocomial sources
Information about integron positive isolates among different sources of S.aureus isolates
| Isolation source(No) | No. of intI1 positive isolates (%) | No. of intI2 positive isolates (%) | No. of intI1 and int2 positive isolates (%) |
|---|---|---|---|
| Abscesses (7) | 4 | 3 | 3 |
| Blood (31) | 24 | 11 | 10 |
| Catheter (5) | 3 | 3 | 3 |
| CSF (1) | 1 | 0 | 0 |
| Eye (2) | 2 | 0 | 0 |
| Nasal (21) | 14 | 1 | 1 |
| Sputum (4) | 2 | 3 | 2 |
| Sternum (5) | 2 | 0 | 0 |
| Throat (3) | 2 | 3 | 2 |
| Urine (28) | 25 | 11 | 11 |
| Wound (31) | 22 | 14 | 12 |
| Synovia (1) | 0 | 0 | 0 |
| Total (139) | 101 (72.6 %) | 49 (35.2 %) | 44 (31.6 %) |
Sizes of variable regions of integron class I cassettes in intI1 positive isolates
| Pattern of integron I cassettes bands (bp) | No. of isolates (%) |
|---|---|
| 500 | 1 (0.99) |
| 750 | 49 (48.5) |
| 800 | 3 (2.9) |
| 1000 | 36 (35.6) |
| 1100 | 1 (0.99) |
| 1200 | 3 (2.9) |
| 1420 | 2 (1.98) |
| 2120 | 1 (0.99) |
| 3110 | 2 (1.98) |
| Without PCR product | 3 (2.9) |
| Total no. of intI1 positive isolates | 101 (100) |
Sizes of variable regions of integron class 2 cassettes inintI2 positive isolates
| Pattern of integronII cassettes bands (bp) | No. of isolates (%) |
|---|---|
| 750 | 8 (16.3) |
| 1238 | 5 (10.2) |
| 2500 | 19 (38.7) |
| Without PCR product | 17 (34.6) |
| Total no. of intI2 positive isolates | 49 (100) |
Fig. 2Schematic representation of the various cassette arrays found in class 1 and class 2 integrons. The arrows display the open reading frames of the different genes. All aadA and aadB genes are presented as white arrows, dhfrA, aacA4, orfD, oxa2, catB, cmlA6, sat2 genes are presented as black, yellow, light grey, grey, blue and light blue arrows respectively. The grey light boxes indicate the 3′ and 5′ CSs of class1 or class 2 integrons
Phenotypic and genotypic characterization of isolates by different length of amplicons
| Strain | Source | Size of 5′CS-3′CS amplicons | Intl gene | Gene cassette array | Integron putative locationa | Resistance phenotype | Accession number |
|---|---|---|---|---|---|---|---|
| Sm59 | wound | 1200 bp | I | blaoxa2 | C | CRO,LEV,TN,E,CD,LZD,RP,PG,OXA,A,S,ATH,GM,CIP,AP,SXT | KF356395 |
| MMS1 | wound | 750 bp | I | aadB | C | CRO,E,CD,PG,A,S,ATHSPC,GM,CIP,AP,TE,C,AK | KF015994 |
| s61 | wound | 750 bp | I | aadB | C | CRO,TN,E,CD,PG,OXA,A,S,SPC,GM,CIP,AP,TE,SXT | KF030468 |
| sm54 | blood | 1200 bp | I | blaoxa2 | C | CRO,LEV,TN,E,CD,LZD,RP,PG,OXA,A,S,ATH,GM,CIP,AP,SXT | KF305707 |
| sa10 | blood | 800 bp | I | aacA4 | C | CRO,LEV,E,CD,LZD,RP,PG,OXA,A,S,ATH,CIP,AP,TE,SXT | KF305706 |
| S232 | blood | 500 bp | I | putative glucose dehydrogenase-hypothetical protein | C | CRO,E,CD,PG,OXA,A,S,SPC,AP,TE | KF411133 |
| MMS2 | abscess | 750 bp | I | aadB | C | CRO,E,CD,PG,A,S,ATH,SPC,GM,CIP,AP,TE,C,AK | KF015995 |
| s74 | blood | 1000 bp | I | aadA2 | C | CRO,TN,E,CD,PG,OXA,A,S,SPC,GM,CIP,AP,TE,SXT | KF411134 |
| s54 | blood | 2120 bp | I | orfD-aacA4-catBB | P | CRO,LEV,E,CD,LZD,PG,OXA,A,S,ATH,SPC,GM,CIP,AP,TE,C,AK | KF411135 |
| s5 | wound | 1100 bp | I | orfD-aacA4 | C | CRO,LEV,E,CD,LZD,PG,OXA,A,S,ATH,SPC,GM,CIP,AP,TE,C,AK | KF411137 |
| s22 | wound | 1000 bp | I | aadA2 | C | CRO,TN,E,CD,PG,OXA,A,S,SPC,GM,CIP,AP,TE,SXT,AK | KF411138 |
| s36 | blood | 1000 bp | I | aadA2 | C | CRO,TN,E,CD,PG,OXA,A,S,SPC,GM,CIP,AP,TE,SXT | KF411139 |
| sm91 | blood | 1420 bp | I | aadB-catB3 | C | CRO,TN,E,CD,PG,OXA,A,S,SPC,GM,APC,SXT | KJ002505 |
| sm105 | wound | 3100 bp | I | aadB-aadA1-cmlA6 | P | CRO,LEV,E,CD,LZD,PG,OXA,A,S,ATH,SPC,GM,CIP,AP,TE,C,SXT,AK | KJ002506 |
| sm22 | wound | 750 bp | II | hdfrA11 | C | CRO,LEV,TN,E,CD,PG,OXA,A,S,SPC,GM,CIP,AP,TE,SXT | KF305708 |
| sm97 | blood | 2500 bp | II | dhfrA1-sat2-aadA1 | P | CRO,LEV,TN,E,CD,PG,OXA,GAT,A,S,ATH,SPC,GM,CIP,AP,TE,C,SXT,AK | KF305710 |
| s92 | blood | 750 bp | II | hypothetical protein | C | CRO,E,CD,PG,OXA,AS,SPC,AP,TE | KF411136 |
| s105 | wound | 1230 bp | II | dhfrA1-sat2 | C | CRO,LEV,TN,E,CD,LZD,RP,PG,OXA,A,S,ATH,GM,AP,SXT | KJ769139 |
a c chromosomal location, P plasmid location, CRO ceftriaxone, LEV levofloxacin, E erythromycin, CD clindamycin, TN tobramycin, PG penicillin G, LZD linezolid, OXA oxacillin, A amoxicillin, S streptomycin, ATH azithromycine, SPC spectinomycin, GM gentamycin, CIP ciprofloxacin, AP ampicillin, TE tetracycline, C chloramphenicol, SXT trimethoprim-sulfamethoxazole, AK amikacin